We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 109

Federal Circuit reverses Patent Appeals Board on obviousness ruling and commercial success evidence
  • Shook Hardy & Bacon LLP
  • USA
  • January 13 2011

The Federal Circuit Court of Appeals has determined that the Board of Patent Appeals and Interferences incorrectly rejected on obviousness grounds a patent claim involving physical and air shields to prevent the clogging of a nozzle to a Wurster coater, which sprays coating material onto pharmaceutical ingredients


Pharma merger activity attributed to “patent cliff”
  • Shook Hardy & Bacon LLP
  • USA
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies


Court dismisses action to correct inventorship of two patents
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

A federal court in Massachusetts has determined that genetic researchers could neither substitute themselves as the inventors of two patents nor correct the patents' inventorship to add their names under 35 U.S.C. 256, because they had not engaged in any collaborative efforts with the named inventors


News Bytes - April 18, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

The U.S. Department of Commerce announces the winners of the U.S. Patent and Trademark Office's Patents for Humanity pilot program. The awards


Myriad Genetics sues diagnostics company over BRCA1 and BRCA2 testing
  • Shook Hardy & Bacon LLP
  • USA
  • July 11 2013

Just weeks after the U.S. Supreme Court determined that naturally occurring human genes are not patent eligible and thus found certain Myriad


News bytes - February 21, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • February 21 2013

The U.S. Patent and Trademark Office schedules a series of public roundtables "to solicit stakeholder input on ways the agency can reduce the number


Myriad Genetics brings new BRCA1BRCA2 infringement suits
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

Myriad Genetics now reportedly has six pending infringement lawsuits involving its BRCA1 and BRCA2 patents, with Invitae Corp. and Laboratory Corp


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • October 18 2012

The U.S. Patent and Trademark Office reopens the comment period on its proposed rulemaking and proposed examination guidelines, published on July 26, 2012, “to implement the first-inventor-to-file provisions of the Leahy-Smith America Invents Act.” Comments may now be submitted until November 5


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • April 3 2014

The U.S. Food and Drug Administration (FDA) announces the availability of draft Guidance for Industry titled "Labeling for Human Prescription Drug


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • May 1 2014

The U.S. Food and Drug Administration (FDA) seeks input "on the design and conduct of the postmarketing requirements (PMRs) for the class-wide